Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

In Western countries, prostate cancer is the most prevalent cancer of men and one of the leading causes of cancer-related death in men. Several genome-wide association studies have yielded numerous common variants conferring risk of prostate cancer. Here, we analyzed 32.5 million variants discovered by whole-genome sequencing 1,795 Icelanders. We identified a new low-frequency variant at 8q24 associated with prostate cancer in European populations, rs188140481[A] (odds ratio (OR) = 2.90; P(combined) = 6.2 × 10(-34)), with an average risk allele frequency in controls of 0.54%. This variant is only very weakly correlated (r(2) ≤ 0.06) with previously reported risk variants at 8q24, and its association remains significant after adjustment for all known risk-associated variants. Carriers of rs188140481[A] were diagnosed with prostate cancer 1.26 years younger than non-carriers (P = 0.0059). We also report results for a previously described HOXB13 variant (rs138213197[T]), confirming it as a prostate cancer risk variant in populations from across Europe.

Original publication

DOI

10.1038/ng.2437

Type

Journal article

Journal

Nat Genet

Publication Date

12/2012

Volume

44

Pages

1326 - 1329

Keywords

Adenocarcinoma, Aged, Aged, 80 and over, Base Sequence, Cell Line, Chromosomes, Human, Pair 8, European Continental Ancestry Group, Gene Frequency, Genetic Predisposition to Disease, Genome, Human, Genome-Wide Association Study, Homeodomain Proteins, Humans, Iceland, Male, Middle Aged, Molecular Sequence Data, Mutation, Polymorphism, Single Nucleotide, Prostatic Neoplasms, Risk, Sequence Analysis, DNA